KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Cash from Financing Activities (2016 - 2025)

NovoCure's Cash from Financing Activities history spans 12 years, with the latest figure at -$559.5 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 20937.77% year-over-year to -$559.5 million; the TTM value through Dec 2025 reached -$451.3 million, down 599.74%, while the annual FY2025 figure was -$451.3 million, 599.74% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$559.5 million at NovoCure, down from $100.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $100.5 million in Q3 2025 and bottomed at -$559.5 million in Q4 2025.
  • The 5-year median for Cash from Financing Activities is $3.5 million (2021), against an average of -$15.2 million.
  • The largest YoY upside for Cash from Financing Activities was 100417.0% in 2025 against a maximum downside of 20937.77% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $3.7 million in 2021, then fell by 6.63% to $3.4 million in 2022, then tumbled by 43.99% to $1.9 million in 2023, then skyrocketed by 40.58% to $2.7 million in 2024, then tumbled by 20937.77% to -$559.5 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Cash from Financing Activities are -$559.5 million (Q4 2025), $100.5 million (Q3 2025), and $2.4 million (Q2 2025).